Status message

Not the entire site translated, but only to "Journal"

INFLUENCE OF SINGLE NUCLEOTIDE VARIANTOF GENE LEP (rs3828942) ON ANTIPSYCHOTIC-INDUCED ABNORMAL GLUCOSE METABOLISMIN PATIENTS WITH SCHIZOPHRENIA

V.S. Dobrodeeva 1, M.Y. Tolmachev 1, N.A. Shnayder 1, Neznanov N.G. 1 , R.F. Nasyrova 1, 2, 3
1
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russia
2 P.P. Kashchenko Psychiatric Hospital No 1, St. Petersburg, Russia
3 Kazan Federal University, Respublica Tatarstan, Kazan, Russia
Purpose: To study the influence of the polymorphic variant of the LEP gene Lys656Asn (rs3828942) on antipsychotic-induced changes in glucose concentration in patients residing in the European part of Russian Federation.
Materials and methods: A prospective study included 117 adult patients based on the presence of F2 disorders according to ICD-10 and the absence of serious somatic disorders residing in the European part of Russian Federation. Patients took antipsychotics in monotherapy.
Results: A allele of Lys656Asn polymorphism (rs3828942) of the LEP gene is associated with glucose concentration more than 6.1 mmol/L during antipsychotic therapy
Conclusions: Genetic polymorphisms of the leptin system (LEP Lys656Asn) could be a predictor of pre-diabetic state development during antipsychotic therapy.
Contact: nreginaf77@gmail.com
Citation:
V.S. Dobrodeeva, M.Y. Tolmachev, N.A. Shnayder, R.f. Nasyrova. Influence of single nucleotide variantof gene LEP (rs3828942) on antipsychotic-induced abnormal glucose metabolismin patients with schizophrenia // Sovrem. ter. psih. rasstrojstv. – 2020. – Vol. 1. – P. 16-20. DOI: 10.21265/PSYPH.2020.37.30.002

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1. Phan S.V., Kreys T.-J.M. Adjunct Mirtazapine for negative symptoms of schizophrenia // Pharmacotherapy [Internet]. – Wiley. – 2011, Oct. – Vol. 31 (10). P. 1017–1030. – Available from: http://dx.doi.org/10.1592/phco.31.10.1017
2. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis // The Lancet [Internet]. – Elsevier BV. – 2009, Jan. – Vol. 373 (9657). –P. 31–41. – Available from: http://dx.doi.org/10.1016/s0140-6736(08)61764-x
3. Meltzer H.Y. The Role of serotonin in antipsychotic drug action // Neuropsychopharmacology [Internet]. – Springer Nature. – 1999, Aug. – Vol. 21. – S. 106–115. – Available from: http://dx.doi.org/10.1038/sj.npp.1395370
4. Foussias G., Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making // The Canadian Journal of Psychiatry [Internet]. – SAGE Publications. – 2010, Mar. – Vol. 55 (3). – P. 117–125. – Available from: http://dx.doi.org/10.1177/070674371005500302
5. Malhotra A.K., Zhang J.-P., Lencz T. Pharmacogenetics in psychiatry: translating research into clinical practice // Molecular Psychiatry [Internet]. – Springer Nature. – 2011, Nov. 15. – Vol. 17 (8). – P. 760–769. – Available from: http://dx.doi.org/10.1038/mp.2011.146
6. Müller D. Pharmacogenetics of antipsychotic-induced weight gain // Pharmacological Research [Internet]. – Elsevier BV. – 2004, Apr, – Vol. 49 (4). – P. 309–329. – Available from: http://dx.doi.org/10.1016/j.phrs.2003.05.001
7. Kyrou I., Randeva H.S., Tsigos C., Kaltsas G., Weickert M.O. Clinical problems caused by obesity [Internet]. – Last Update: January 11, 2018. – Available from: https://www.ncbi.nlm.nih.gov/books/NBK278973/
8. Meyer J.M. Novel antipsychotics and severe hyperlipidemia // Journal of Clinical Psychopharmacology [Internet]. – Ovid Technologies (Wolters Kluwer Health). – 2001, Aug. – Vol. 21 (4). – P. 369–374. – Available from: http://dx.doi.org/10.1097/00004714-200108000-00003
9. The IDF consensus worldwide definition of the metabolic syndrome // Obesity and metabolism [Internet]. – Endocrinology Research Centre. – 2005, Sep. – Vol. 15 (3). – P. 47. – Available from: http://dx.doi.org/10.14341/2071-8713-4854
10. Allison D.B., Mentore J.L., Heo M. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis // Am. J Psychiatry. – 1999. –Vol. 156 (11). – P. 1686–1696.
11. Gregoor J.G., van der Weide J., Loovers H.M., van Megen H.J., Egberts T.C., Heerdink E.R. Polymorphisms of the LEP, LEP and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting // Pharmacogenomics [Internet]. – Future Medicine Ltd. – 2011, Jun. – Vol. 12 (6). – P. 919–923. – Available from: http://dx.doi.org/10.2217/pgs.11.40
12. Ruaño G., Goethe J.W., Caley C., Woolley S., Holford T.R., Kocherla M. et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients // Molecular Psychiatry [Internet]. – Springer Nature. – 2007, Jan 2. – Vol. 12 (5). P. 474–482. – Available from: http://dx.doi.org/10.1038/sj.mp.4001944
13. Ringen P.A., Engh J.A., Birkenaes A.B., Dieset I., Andreassen O.A. Increased mortality in schizophrenia due to cardiovascular disease: A non-systematic review of epidemiology, possible causes, and interventions // Frontiers in Psychiatry [Internet]. – Frontiers Media SA. – 2014, Sep. – Vol. 26. – P. 5. – Available from: http://dx.doi.org/10.3389/fpsyt.2014.00137
14. Minet-Ringuet J., Even P.C., Valet P., Carpéné C., Visentin V., Prévot D. et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment // Molecular Psychiatry [Internet]. – Springer Nature. – 2007, Jan. 9. – Vol. 12 (6). – P. 562–571. – Available from: http://dx.doi.org/10.1038/sj.mp.4001948
15. Varela L., Horvath T.L. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis // EMBO reports [Internet]. – Wiley. – 2012, Nov. 13. – Vol. 13 (12). – P. 1079–1086. – Available from: http://dx.doi.org/10.1038/embor.2012.174
16. Vaisse C., Halaas J.L., Horvath C.M., Darnell J.E., Stoffel M., Friedman J.M. Leptin activation of Stat3 in the hypothalamus of wild–type and ob/ob mice but not db/db mice // Nature Genetics [Internet]. – Springer Nature. – 1996, Sep. – Vol. 14 (1). – P. 95–97. Available from: http://dx.doi.org/10.1038/ng0996-95
17. Mesaros A., Koralov S.B., Rother E., Wunderlich F.T., Ernst M.B., Barsh G.S. et al. Activation of Stat3 signaling in AgRP neurons promotes locomotor activity // Cell Metabolism [Internet]. – Elsevier BV. – 2008, Mar. –Vol. 7 (3). –P. 236–248. – Available from: http://dx.doi.org/10.1016/j.cmet.2008.01.007 
18. Van den Top M., Lee K., Whyment A.D., Blanks A.M., Spanswick D. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus // Nature Neuroscience [Internet]. – Springer Nature. – 2004, Apr. 18. – Vol. 7 (5). – P. 493–494. – Available from: http://dx.doi.org/10.1038/nn1226